Suppliers / Matrix Pharmacorp

Matrix Pharmacorp

India 646 employees Updated 9 July 2026

Matrix Pharmacorp is an API manufacturer based in India. It holds 223 active US drug master files. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 28 November 2025 as VAI. Customs aggregates show $7.4M of exports covering 51 molecules to 16 destinations in 2025.

223
active US DMFs
0
valid CEPs
5
registered plants 5 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
5 of 5 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 28 November 2025 VAI US FDA
  • 7 November 2025 VAI US FDA
  • 5 September 2025 VAI US FDA
  • 5 May 2023 NAI US FDA
  • 17 September 2022 VAI US FDA
  • 23 November 2019 VAI US FDA
  • 5 June 2019 OAI US FDA
  • 8 February 2019 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Vizianagaram, India 3002785310
Visakhapatnam, India 3008861594
Hyderabad, India 3003227156
Visakhapatnam, India 3009590042
Hyderabad, India 3004713397

What they file, and where

Molecule Regulators Docs
Darunavir US FDA 3
Efavirenz US FDA 3
Emtricitabine US FDA 3
Esomeprazole US FDA 3
Paliperidone US FDA 3
Tenofovir Disoproxil US FDA 3
Alprazolam US FDA 2
Aripiprazole US FDA 2
Atazanavir US FDA 2
Cabotegravir US FDA 2
Show all 30 molecules on file
Canagliflozin US FDA 2
Carvedilol US FDA 2
Dolutegravir US FDA 2
Eletriptan US FDA 2
Elvitegravir US FDA 2
Epinephrine US FDA 2
Felbamate US FDA 2
Iron Sucrose US FDA 2
Lamivudine US FDA 2
Lanthanum Carbonate US FDA 2
Mafenide US FDA 2
Nepafenac US FDA 2
Phentolamine US FDA 2
Pomalidomide US FDA 2
Raltegravir US FDA 2
Sertraline US FDA 2
Stavudine US FDA 2
Sugammadex US FDA 2
Tetrabenazine US FDA 2
Valganciclovir US FDA 2

Also appears on these molecule pages

Show 40 more molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 3

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $14.0M 29
2025 Not reported $7.4M 16

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Matrix Pharmacorp comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 28 November 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts